The biopharmaceutical industry has been through a tremendous period of company creation, and even with a drop in financings during 2022 and 2023 from record levels of funding in 2020 and 2021, the last two years have not been far off from all-time high levels of investment in drug development. That means a lot of newly created companies have put capital to work against early-stage goals and now they are looking to raise their next round of funding in a financial market that is still in recovery.
That’s where the newly formed Symbiotic Capital hopes to come in. Calling itself a first-of-its-kind global life science credit firm, Symbiotic is affiliated with Bellco Capital, the Los Angeles-based investment firm founded by biotechnology entrepreneur Arie Belldegrun, the former founder and CEO of Gilead Sciences, Inc.-acquired Kite Pharma, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
